SHA: 600645

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has entered into a definitive agreement with PepStar Therapeutics Limited to acquire its lead asset, HCXT‑2001, an investigational Phase I oral IL‑23…

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

CompanyDrug

Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis

CompanyDrug

Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis

CompanyDrug

Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials

CompanyDrug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

CompanyDrug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Show More